obesity

Over the past five years, medications called GLP-1s have revolutionized the treatment of metabolic disorders like obesity, diabetes and fatty liver diseases.

Weight loss is often measured by one number: the number on the scale. But what if we looked beyond weight and asked what is actually changing inside the body? Our recent study explored how a moderate calorie deficit combined with aerobic exercise can influence body composition adults with obesity.

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

Endocrine Society experts will discuss its brand-new Scientific Statement on research in the new era of obesity medicines and how this publication is part of a broader Center on Obesity initiative during a virtual news conference on September 9.

Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.

Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.

Obesity and its related complications have become an important public health concern. Traditional lifestyle modification and earlier pharmacotherapies provide only limited weight reduction. There is an urgent need for more effective treatments. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1 RA). Its distinctive pharmaco…

New research examines the emerging benefits and unanswered questions surrounding this rapidly expanding class of medications. Millions of people are now using GLP-1 receptor agonists and dual agonists to treat obesity and other metabolic diseases, giving researchers a much broader view of what these medications can do beyond their intended effects. An editorial by Dr. [...]

Medicines first developed to improve blood sugar control have quickly changed the treatment of obesity. Now scientists are finding that GLP-1 drugs may affect far more than body weight, with possible benefits ranging from heart health to inflammation and even addictive behavior. Dr. Steven Heymsfield of LSU’s Pennington Biomedical Research Center and Dr. Adam Gilden […] The post Weight Loss Drugs…

Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of “brake” on fullness signals. The discovery helps explain why very different obesity drugs can achieve similar results and suggests that carefully …

A review suggests that precision nutrition can enhance the effectiveness of GLP-1 treatments for obesity and type 2 diabetes after exploring the biological mechanisms involved in the medications. The mechanisms studies focused on nutrition, body composition, gut microbiome, inflammation, metabolism, and genetics.

Obesity is a global health concern that can contribute to diabetes, cardiovascular disease, and other metabolic disorders.

OnLine Journal of Biological Sciences, Published online: 11 August 2026; doi:10.3844/ojbsci.2026.26.03.052 Purpose of Review: Obesity is increasingly recognized as an immune endocrine disorder rather than only a metabolic condition. This review critically examines how adipokines particularly adiponectin, r...

Weight-loss drugs such as semaglutide have attracted enormous attention among adults, but researchers are increasingly asking whether they can safely help younger people living with obesity. A new analysis suggests GLP-1 medicines can produce meaningful weight loss in adolescents without diabetes, although important questions remain about long-term use. The findings were presented at the Internat…

Medicines that have transformed obesity treatment in adults may also help teenagers with obesity lose weight, according to a new review of clinical trials. Researchers found that GLP-1 drugs reduced body weight and improved several other health measures in children and adolescents without diabetes. The research was presented at the International Congress on Obesity 2026 […] The post Weight-Loss D…

Obesity-driven synaptic dysfunction is increasingly recognized as a key mechanism linking metabolic disorders to neurodegenerative diseases. This review aims to explore the utility of zebrafish (Danio rerio) as a translational model to investigate these mechanisms and screen peptide-based therapeutic strategies. Owing to their optical transparency, genetic tractability, and suitability for high-t…

An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a small molecule that can be taken once daily with or without food and could potentially be produced more easily at scale.

Scientists comment on the Medicines and Healthcare products Regulatory Agency (MHRA) authorising the orforglipron obesity pill.    Dr Marie Spreckley, … read more

OnLine Journal of Biological Sciences, Published online: 9 August 2026; doi:10.3844/ojbsci.2026.26.01.010 The rising prevalence of obesity and type 2 diabetes mellitus (T2DM) has emerged as one of the most pressing global public health challenges, profoundly impacting various demographic groups worldwide....

An oral GLP-1 drug showed promising weight loss results in a phase II trial. A pill-based approach to GLP-1 treatment helped adults with obesity or overweight lose as much as 12 percent of their body weight over 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine. The study tested aleniglipron, [...]